Goldman Sachs raises Abbvie stock price target on growth confidence By Investing.com

AbbVie reported Q1 2026 adjusted EPS of $2.65 versus $2.59 expected and revenue of $15.0B, beating estimates by about $300M, but the stock still fell in pre-market trading to $189.28 from $197.69. Goldman Sachs raised its price target to $244 from $240 and said management’s confidence in Skyrizi and Rinvoq, plus positive Crohn’s disease pipeline data, could support a tactical relief rally. Investors remain focused on capex-heavy outlook risks and upcoming readouts across lutikizumab, Rinvoq, Qulipta, Ubrelvy, and Temab-A.

Analysis

ABBV is setting up as a classic “good numbers, weak tape” setup: the market is still discounting a post-Humira durability problem even as management is signaling the next leg of earnings power is more visible than the consensus model. The second-order implication is that every incremental beat on the immunology franchise should compress the perceived terminal multiple risk, because the debate shifts from “is the bridge real?” to “how much of the bridge is already in the stock.”

The bigger competitive read-through is to JNJ and other late-entering autoimmune players: if a new oral entrant can only pressure at the margin while ABBV’s combo data suggests a stronger efficacy stack, then share loss risk may be slower and more price-sensitive than feared. That matters because the market usually overweights launch headlines and underweights persistence, adherence, and physician inertia; if persistence data do not deteriorate, the competitive threat may prove more tactical than structural over the next 2-3 quarters.

The main risk is not the current quarter; it is the cadence of pipeline proof over the next 6-12 months. Any disappointment in the upcoming readouts would likely hit the stock harder than a routine miss because the valuation support is now tied to a “multiple years of visibility” narrative, not just one-quarter execution. Conversely, if management keeps converting pipeline optionality into revenue visibility, the stock can rerate quickly despite the existing overvaluation screen, because income-oriented holders will defend the name on yield and dividend growth.

Contrarian take: the consensus is likely underappreciating how much capital rotation ABBV can attract if biotech risk appetite stays constrained. In a market that is punishing long-duration growth, a high-cash-return healthcare compounder with a credible late-stage bridge can act like a bond proxy plus growth optionality, which can sustain relative strength even if absolute upside is modest.

Key Decisions for Investors

• Initiate a tactical long ABBV position over the next 2-6 weeks with a 3-5% downside stop; target a 8-12% rerating if the market starts pricing the post-Humira bridge as durable rather than uncertain.
• Use ABBV call spreads expiring after the next two catalyst windows to express upside with defined risk; best setup is a moderate-premium structure where the stock only needs a mid-single-digit move to pay.
• Pair trade: long ABBV / short JNJ into upcoming autoimmune and oral-therapy news flow; thesis is that ABBV’s execution and combo optionality can outperform the “new entrant” narrative over the next 1-2 quarters.
• If already long ABBV, trail profits but do not fully exit ahead of pipeline readouts; the asymmetry is better for holding a core stake into catalysts than trying to trade every headline.
• Watch for any guidance reset on the 2026-2028 earnings bridge; a confirmation would likely trigger a fast mean reversion in the stock, while any crack would argue for de-risking immediately.